系统性硬化症相关肺动脉高压的内皮生物标志物
研究检测系统性硬化症(SSc)患者中不对称二甲基精氨酸(ADMA)、可溶性内皮糖蛋白(sEng)和正五聚蛋白-3(PTX-3)三种内皮生物标志物,比较健康对照、SSc相关肺动脉高压(SSc-PH)、高PH风险特征及低PH风险特征四组。PTX-3在低风险组显著低于其他组,且对区分低风险与高风险有较高判别能力,并可区分左心疾病相关PH与PAH或ILD相关PH;ADMA和sEng在四组间无差异。作者认为PTX-3是有前景的PH风险状态生物标志物及毛细血管前PH的可能标志物,需在外部队列中验证。
要点
- PTX-3在SSc低PH风险组显著低于其他组,区分低风险与高风险的ROC曲线下面积为0.87(95%CI 0.76-0.98,P=0.0002)。
- PTX-3在左心疾病相关SSc-PH组显著低于PAH组和ILD组。
- ADMA和sEng在健康对照、SSc-PH、高PH风险及低PH风险四组间无差异。
核心结论
- PTX-3是SSc患者PH风险状态的有前景生物标志物,也可能是毛细血管前PH的标志物,应在外部队列中验证。
研究设计与样本
- 采用酶联免疫吸附试验测定四组人群的ADMA、sEng和PTX-3:18例健康对照、74例SSc-PH患者、44例具有高PH风险特征的患者和10例具有低PH风险特征的患者。
- 高PH风险特征包括:一氧化碳弥散量(DLco)小于55%且用力肺活量(FVC)大于70%,或FVC/DLco比值大于1.6,或超声心动图右心室收缩压大于或等于40 mm Hg。
- 比较四组间ADMA、sEng和PTX-3水平,并按SSc-PH三种临床分类(肺动脉高压[PAH]、左心疾病和间质性肺病[ILD])进行分层分析。
主要发现
- PTX-3在SSc低PH风险组显著低于其他组,中位数27.0 pg/ml(四分位距19.0-47.3),P<0.003。
- PTX-3区分PH患者低风险与高风险的ROC曲线下面积为0.87(95%置信区间0.76-0.98,P=0.0002)。
- PTX-3在左心疾病相关SSc-PH组为57.5 pg/ml(四分位距39.8-79.0),显著低于PAH组85.5 pg/ml(四分位距56.3-104.5)和ILD组90.3 pg/ml(四分位距74.9-111.0),P<0.01。
- ADMA和sEng在四组间无差异。
关键数值与推荐
- 高PH风险特征标准:DLco小于55%且FVC大于70%,或FVC/DLco比值大于1.6,或超声心动图右心室收缩压大于或等于40 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出PTX-3应在外部队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite efforts at early detection, patients with systemic sclerosis (SSc) pulmonary hypertension (PH) present with advanced disease. We sought to determine whether endothelial biomarkers (asymmetric dimethylarginine [ADMA], soluble endoglin [sEng], and pentraxin-3 [PTX-3]) can determine SSc-PH risk or differentiate between SSc-PH subgroups. METHODS: ADMA, sEng, and PTX-3 were measured by enzyme-linked immunosorbent assay in four groups: 1) 18 healthy controls, 2) 74 patients with SSc-PH, 3) 44 patients at high risk for PH features, and 4) 10 patients with low risk for PH features. High-risk features included a diffusion capacity (DLco) less than 55% with a forced vital capacity (FVC) greater than 70%, an FVC/DLco ratio of >1.6, or a right ventricular systolic pressure on an echocardiogram greater than or equal to 40 mm Hg. ADMA, sEng, and PTX-3 were compared between these four groups as well as stratified based on the three SSc-PH clinical classification groups (pulmonary arterial hypertension [PAH], left-heart disease, and interstitial lung disease [ILD]). RESULTS: PTX-3 was significantly lower in subjects with SSc at low risk for PH (median 27.0 pg/ml [interquartile range (IQR) 19.0-47.3]; P < 0.003) than the other groups. The area under the receiver operating characteristic curve was 0.87 (95% confidence interval 0.76-0.98, P = 0.0002) to differentiate low risk from high risk for patients with PH. PTX-3 was significantly lower in SSc-PH from disease of the left side of the heart (57.5 pg/ml [IQR 39.8-79.0]; P < 0.01) compared to SSc-PH from either PAH (85.5 pg/ml [IQR 56.3-104.5]) or ILD (90.3 pg/ml [IQR 74.9-111.0]). Neither ADMA nor sEng differed between the four groups. CONCLUSION: PTX-3 is a promising biomarker of PH risk status in patients with SSc as well as a possible marker of precapillary PH, which should be validated in an external cohort.
引用
- Lammi MR, Kolstad KD, Saketkoo LA, et al. Endothelial Biomarkers of Systemic Sclerosis-Associated Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2023. PMID: 37365746. doi:10.1002/acr.25180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。